There is currently a shortage of the RSV vaccine for infants due to higher-than-anticipated demand.
The long-acting monoclonal antibody immunization Beyfortus (nirsevimab) is recommended by the CDC for preventing respiratory syncytial virus (RSV) in children up to 24 months old.
The shortage primarily affects 100 mg-dose prefilled syringes used for infants weighing less than 11 pounds. (Trending: Judge Declines To Recuse From Trump 2024 Ballot Case)
Sanofi, the maker of Beyfortus, is working with the CDC and AstraZeneca to ensure equitable distribution.
A Sanofi spokesperson said, “For the first time in history, health care providers are able to help protect an extraordinary number of infants against RSV disease.”
They added, “Despite an aggressive supply plan built to outperform past pediatric immunization launches, demand for this product, especially for the 100-mg doses used primarily for babies born before the RSV season, has been higher than anticipated.”
Dr. Denise Scott, a JustAnswer expert pediatrician said “As a pediatrician, I have always dreaded RSV season, knowing how much illness it creates in babies and how many hospitalizations.”
“Because it is a viral infection, there is no specific treatment or cure, only supportive therapy,” warned Dr. Scott. (Trending: It’s Time For Donald Trump To Drop Out)
The CDC recommends prioritizing available doses for infants at the highest risk and suspending the use of nirsevimab for certain age groups.
Families are advised to take preventive measures to limit the spread of RSV.
RSV can be serious, especially for infants under 6 months old or those with underlying conditions.
The RSV vaccine can reduce hospitalizations by 80%.
Most Popular:
Ex-Obama Official Says Trump Will ‘Likely’ Be Jailed
Democrat Testifies in Trump Case
Will ‘MAGA Mike’ Succeed as House Speaker?
